Cargando…
Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer
Ovarian cancer is the most lethal gynecologic malignancy among women. Approximately 70–80% of patients with advanced ovarian cancer experience relapse within five years and develop platinum-resistance. The short life expectancy of patients with platinum-resistant or platinum-refractory disease under...
Autores principales: | Ryu, Joohyun, Thomas, Stefani N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125593/ https://www.ncbi.nlm.nih.gov/pubmed/34063568 http://dx.doi.org/10.3390/molecules26092674 |
Ejemplares similares
-
Impact of VALID Act implementation on mass spectrometry-based clinical proteomic laboratory developed tests
por: Lin, Yanchun, et al.
Publicado: (2023) -
Advances in mass spectrometry-based clinical biomarker discovery
por: Crutchfield, Christopher A., et al.
Publicado: (2016) -
Mass spectrometry-based proteomics techniques and their application in ovarian cancer research
por: Swiatly, Agata, et al.
Publicado: (2018) -
Development of biomarkers of genitourinary cancer using mass spectrometry-based clinical proteomics
por: Chen, Yi-Ting, et al.
Publicado: (2018) -
Mass Spectrometry-Based Label-Free Quantitative Proteomics
por: Zhu, Wenhong, et al.
Publicado: (2010)